Department of Biomedicine, University of Basel, 4058, Basel, Switzerland.
Swiss Institute of Bioinformatics, 4053, Basel, Switzerland.
Oncogene. 2021 Jan;40(1):12-27. doi: 10.1038/s41388-020-01508-4. Epub 2020 Oct 12.
Despite major progress in breast cancer research, the functional contribution of distinct cancer cell clones to malignant tumor progression and metastasis remains largely elusive. We have assessed clonal heterogeneity within individual primary tumors and metastases and also during the distinct stages of malignant tumor progression using clonal tracking of cancer cells in the MMTV-PyMT mouse model of metastatic breast cancer. Comparative gene expression analysis of clonal subpopulations reveals a substantial level of heterogeneity across and also within the various stages of breast carcinogenesis. The intra-stage heterogeneity is primarily manifested by differences in cell proliferation, also found within invasive carcinomas of luminal A-, luminal B-, and HER2-enriched human breast cancer. Surprisingly, in the mouse model of clonal tracing of cancer cells, chemotherapy mainly targets the slow-proliferative clonal populations and fails to efficiently repress the fast-proliferative populations. These insights may have considerable impact on therapy selection and response in breast cancer patients.
尽管在乳腺癌研究方面取得了重大进展,但不同癌细胞克隆对恶性肿瘤进展和转移的功能贡献在很大程度上仍难以捉摸。我们使用转移性乳腺癌的 MMTV-PyMT 小鼠模型评估了单个原发性肿瘤和转移瘤内以及恶性肿瘤进展的不同阶段的克隆异质性。对克隆亚群的比较基因表达分析显示,在乳腺癌发生的各个阶段以及不同阶段之间存在相当大的异质性。这种阶段性内的异质性主要表现为细胞增殖的差异,在 luminal A 型、luminal B 型和 HER2 富集型人类乳腺癌的浸润性癌中也发现了这种差异。令人惊讶的是,在癌细胞克隆追踪的小鼠模型中,化疗主要针对增殖缓慢的克隆群体,而不能有效地抑制增殖较快的群体。这些发现可能对乳腺癌患者的治疗选择和反应产生重大影响。